Status:

COMPLETED

Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence

Lead Sponsor:

University of Pennsylvania

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Asthma

Lung Diseases

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

This is a randomized, controlled study that will compare two medication adherence strategies in adults with moderate or severe persistent asthma as a method for improving or maintaining treatment adhe...

Detailed Description

Low-income minority adults have excessively high rates of morbidity from asthma. Poor medication adherence has been documented in these individuals and contributes to the high morbidity level. This st...

Eligibility Criteria

Inclusion

  • Receiving treatment for asthma at one of the participating clinics
  • Moderate or severe persistent asthma according to the NHLBI Guidelines
  • Current use of prescribed inhaled corticosteroids
  • Evidence of reversible airflow obstruction, as indicated by the following two criteria:
  • FEV1pp AND less than 80% at the time of study entry or within the 3 years prior to study entry
  • An increase of greater than 15% and 200ml in FEV1 with asthma treatment over the last 3 years (if there is no record of such improvement, participants will be evaluated via spirometry pre- and post-bronchodilator at the first study visit. An increase in FEV1 or FVC greater than 12% and 200 ml in FEV1 30 minutes following albuterol administration will represent evidence of reversible airflow obstruction. If a spirometer is not immediately available, participants may be evaluated using a peak flow meter, which reports a PEF. A PEFpp less than 80% and an improvement of at least 60 L per minute after the administration of albuterol will represent evidence of reversible airflow obstruction)
  • Has a functional telephone or mobile phone

Exclusion

  • Significant lung or cardiac disease (other than hypertension)
  • Psychiatric illness, such as mania or schizophrenia, that may make it impossible to understand or carry out the Problem Solving intervention

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

397 Patients enrolled

Trial Details

Trial ID

NCT00115323

Start Date

May 1 2005

End Date

March 1 2010

Last Update

December 23 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104